Davidson Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Davidson Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	-$3K	–	97
2021 Q4	$3K	Hold	4	–	–	﹤0.01%	81
2021 Q3	$2K	Hold	4	–	–	﹤0.01%	85
2021 Q2	$2K	Sell	4 -2,250	-100%	-$1.14M	﹤0.01%	83
2021 Q1	$1.07M	Buy	2,254 +879	+64%	+$428K	0.56%	64
2020 Q4	$664K	Buy	1,375 +52	+4%	+$28.1K	0.37%	55
2020 Q3	$741K	Buy	1,323 +41	+3%	+$24.9K	0.47%	45
2020 Q2	$800K	Sell	1,282 -614	-32%	-$349K	0.7%	35
2020 Q1	$926K	Buy	+1,896	New	+$782K	1.32%	18

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Davidson Capital Management's REGN Position: Q1 2022 in Review

Davidson Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 4 shares — an estimated $3K sold.

Davidson Capital Management first reported a position in REGN in Q1 2020 and held it in 8 quarters. The position peaked at $1.07M in Q1 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Davidson Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Davidson Capital Management sold 4 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $3K.
Davidson Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 8 quarters.
Davidson Capital Management's Regeneron Pharmaceuticals position peaked at $1.07M in Q1 2021.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Davidson Capital Management's 13F filing for Q1 2022, filed 17 May 2022.